NCT00821821已完成2 期
A Phase IIa, Multi-centre, Randomised, Double-blind, Placebo Controlled, Clinical Study Investigating the Safety, Tolerability and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
Shionogi6 个研究点 分布在 3 个国家目标入组 36 人开始时间: 2009年2月28日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
- 试验地点
- 6
- 主要终点
- Number of Participants That Experienced Adverse Events
研究概览
简要总结
The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological assessments data of MCI-186 in subjects with acute ischemic stroke.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Full functional independence prior to the present stroke (as evidenced by a pre-morbid modified Rankin Scale score of 0-2
- •Clinical diagnosis of acute stroke with CT scan ruling out intracranial hemorrhage
- •Onset of symptoms within 1-24 hours of commencement of infusion of study drug
- •Measurable deficit on NIHSS (as evidenced by a score of 3-15)
- •Full consciousness (i.e. the score for NIHSS item 1a=0)
- •Written valid informed consent is obtained from the subject or his/her next of kin or legal representative if the subject is fully conscious (i.e. the score for NIHSS item 1a = 0) but unable to read and/or sign the ICF, in accordance with National legislation and local IRB requirements
排除标准
- •Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition
- •Subjects with severe illness with life expectancy less than 6 months
- •Body weight in excess of 120 kg
- •Subjects who have received rTPA or other thrombolytics (e.g. urokinase, streptokinase, reteplase, tenecteplase) within the previous 24 hours
- •Likelihood of forbidden concomitant therapy such as vascular surgery, coronary artery bypass graft (CABG), valve replacement, or carotid endarterectomy (CEA)
- •Evidence of cerebral herniation
- •Subjects with confounding neurological diseases such as dementia
- •Subjects with CADASIL, Moya Moya, or carotid dissection
- •Subjects who have experienced a stroke within the previous 3 months (Note: subjects who have recently experienced a TIA, but whose premorbid mRS prior to their stroke is 0-2, will be allowed to enter the study)
- •Evidence from admission imaging tests of infarction involving >1/3 of MCA territory, or entire ACA territory involvement, or internal carotid artery (ICA) occlusions without coexisting separate occlusion of the middle cerebral artery (because of the difficulty distinguishing between chronic and acute ICA lesions in such subjects)
- •Pathology other than cerebral infarction on any admission imaging tests (e.g. ICH or SAH, AV malformation, cerebral aneurysm, or cerebral neoplasm)
- •Current or previous known excessive alcohol use or dependence
- •Current known illicit drug use or dependence
- •Participation in a previous clinical study within 30 days
- •Subjects unlikely to be able and willing to attend all study follow-up visits
- •Any other conditions which in the opinion of the investigator deem the subject ineligible for inclusion
- •Females who are pregnant or intend to become pregnant or subjects (male and female) who do not agree to use effective contraception for 3 months after end of treatment
研究组 & 干预措施
Placebo Group
Placebo Comparator
干预措施: Placebo (Drug)
MCI-186
Experimental
干预措施: MCI-186 (Drug)
结局指标
主要结局
Number of Participants That Experienced Adverse Events
时间窗: 87days
Additional Outcome Measures are included in Tables for Serious Adverse Events and Other Adverse Events to report their numbers and frequency.
次要结局
- Plasma MCI-186 Pharmacokinetics(72 hours)
- mRS, NIHSS, Barthel Index(throughout study)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature EjaculationPremature EjaculationNCT00556478Plethora Solutions Ltd256
终止
2 期
A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)Bronchiolitis Obliterans Syndrome (BOS)GVHD, ChronicStem Cell Transplant ComplicationsNCT04107675Zambon SpA6
已完成
2 期
Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With SulfonylureaType 2 Diabetes MellitusNCT00455598Ionis Pharmaceuticals, Inc.88
已完成
2 期
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne VulgarisAcne VulgarisNCT02661958Sol-Gel Technologies, Ltd.726
已完成
2 期
Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT00458016Ligand Pharmaceuticals105